Karl Rove Drops Bad News For Trump Live On Fox News

Longtime Republican strategist Karl Rove delivered some bad news to Donald Trump and his supporters over the weekend.

“Take a look at the evidence,” he said on Fox News on Saturday when asked if polls have shifted since the former president’s conviction last month on 34 charges in the Stormy Daniels hush money case.

He said polls show Trump losing ground to President Joe Biden since the conviction. As a result, Trump’s modest lead over Biden has been shrinking on RealClearPolitics and other poll aggregators, and Rove predicted that Trump’s lead may be about to vanish altogether.

“We’re likely to see that lead dissipate because the most recent polls have had Biden ahead,” Rove said in comments posted on Mediaite, using his white board to show poll results since the conviction.

Much of that shift is from a core group of voters who may ultimately decide the election.

“The movement is among independents,” said Rove, who helped lead George W. Bush’s two presidential campaigns. “And they have moved, in recent polls, roughly nine points towards Biden.”

Rove noted that polls of independents have previously found that 21 percent have said they would be less likely to vote for Trump if he’s convicted.

Trump and Biden will meet for their first debate since the 2020 election on Thursday evening.


Source link

Dear David: How do I help my daughters deal with their social anxiety?

Teenage girl on her way to school going out her front door. We see her from behind going out the door and holding it open. She is wearing a back pack and a denim jacket. Shot from the knees up.

Melanie Acevedo/Getty Images

Thank you to everyone who proposed questions for my new evidence-based advice column. This time, I am responding to a reader who is concerned about his daughters’ social anxiety. “For one of them, this is so high that she feels unable to ever start a conversation with someone outside of the immediate family,” he tells me. How can he help?

It is a major dilemma for many parents. Social anxiety affects adults and children alike, but it seems to be especially problematic in the second decade of life, with the US National Institute of Mental Health estimating that around…


Source link

Man dies three months after hit-run crash on Brooklyn expressway


An elderly Long Island man has died after clinging to life for three months in the wake of an horrific hit-run crash on a Brooklyn expressway, police said Sunday.

Athanasios Athanasiou, 77, of Farmingdale, was behind the wheel of a Honda CRV on the Gowanus Expressway near 86th St. on March 15 at 12:15 a.m., when he was rear-ended by a Jeep Wrangler, cops said.

The crash impact pushed Athanasiou’s car into a concrete barrier that separates the westbound and eastbound lanes of the expressway. The Jeep driver abandoned the vehicle and took off on foot, leaving Athanasiou on the roadway, according to police.

Athanasiou was taken to NYU Langone Hospital—Brooklyn for head and body injuries, and was eventually transferred to Mount Sinai Hospital, where he died Thursday, police said.

Police are still searching for the Jeep driver.

 


Source link

New GLP-1 drugs promise weight loss and health benefits


The next wave of obesity drugs is coming soon.

Drug companies are racing to develop GLP-1 drugs following the blockbuster success of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound.

Some of the experimental drugs may go beyond diabetes and weight loss, improving liver and heart function while reducing side effects such as muscle loss common to the existing medications. At the 2024 American Diabetes Association conference in Orlando, Florida, researchers are expected to present data on 27 GLP-1 drugs in development.

“We’ve heard about Ozempic and Mounjaro and so on, but now we’re seeing lots and lots of different drug candidates in the pipeline, from very early-stage preclinical all the way through late-stage clinical,” said Dr. Marlon Pragnell, ADA’s vice president of research and science. “It’s very exciting to see so much right now.”

A large portion of the data presented comes from animal studies or early-stage human trials. However, some presentations include mid-to late-stage trials, according to a list shared by the organization.

Approval by the Food and Drug Administration is likely years away for most. Some of the drugs showcased could be available for prescription in the U.S. within the next few years.

“We’ve witnessed an unprecedented acceleration in the development of GLP drugs,” said Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in Cary, North Carolina. “We are now firmly entrenched in the era of the GLP.”

While the existing drugs are highly effective, new drugs that are more affordable and have fewer side effects are needed, McGowan added.

There aren’t just GLP-1 drugs in the pipeline. On Thursday, ahead of the diabetes conference, Denmark-based biotech firm Zealand Pharma released data that showed a high dose of its experimental weight loss drug petrelintide helped reduce body weight by an average of 8.6% at 16 weeks.

The weekly injectable medication is unique because it mimics the hormone amylin, which helps control blood sugar. The hope is patients will experience fewer side effects like nausea commonly associated with GLP-1 drugs such as Wegovy and Zepbound.

Can glucagon hormone help with weight loss?

GLP-1 medications work, in part, by slowing down how quickly food passes through the stomach, leading people to feel fuller longer. In several of the upcoming weight loss drugs, a different hormone called glucagon is in the spotlight. Glucagon is a key blood-sugar-regulating hormone that can mimic the effects of exercise.

One of the drugs featured at the conference on Sunday is called pemvidutide, from Maryland-based biotech firm Altimmune.

The drug contains the GLP-1 hormone, a key ingredient in Ozempic and Wegovy, in addition to glucagon.

Altimmune released data from a phase 2 trial of 391 adults with obesity or who are overweight with at least one weight-related comorbidity such as high blood pressure. Patients were randomized to either get one of three doses of pemvidutide or a placebo for 48 weeks.

Researchers found that patients who got the highest dose of the drug lost on average 15.6% of their body weight after 48 weeks, compared to the 2.2% body weight loss seen in patients who got a placebo. In similar trials, semaglutide was shown to reduce body weight by around 15% after 68 weeks.

These are not direct comparisons because the drugs weren’t compared in a head-to-head clinical trial.

Dr. Scott Harris, Altimmune’s chief medical officer, said the drug has been shown to help people lose weight, as well as provide health benefits to the liver and heart. What’s more, the drug has shown benefits in preserving lean body mass. Some studies have suggested that semaglutide, the active ingredient in Ozempic and Wegovy, can cause muscle loss.

“If people take the drugs long term, what’s going to be their long-term health? What’s going to be the long-term effects on their body composition, their muscle, their ability to function?” he said.

Harris said that people who got pemvidutide lost on average 21% of their lean body mass, which is lower than the around 25% of lean body mass people typically lose with diet and exercise.

“We’re the next wave of obesity drugs,” Altimmune President and CEO Vipin Garg said. “The first wave of mechanisms was all driven by appetite suppression. We are adding another component.”

Altimmune expects to begin a phase 3 trial soon. The company hopes the drug will be available in the U.S. sometime in 2028.

Competition could drive down costs

Expanding the number of weight loss drugs available is important for several reasons, experts say.

More options could also help alleviate the shortages seen in the U.S. with Novo Nordisk’s and Lilly’s weight loss drugs.

Latest news on weight loss medications

Increased competition could drive down the high cost of the drugs over time. A month’s supply of Wegovy or Zepbound can cost more than $1,000, often financially untenable for many patients, experts say.

Patients can also respond differently to treatments, said Dr. Fatima Cody Stanford, an associate professor of medicine and pediatrics at Harvard Medical School. In fact, some have found the existing GLP-1 options ineffective.

“Different GLP-1 drugs may have varying levels of efficacy and potency,” she said. “Some patients may respond better to one drug over another, depending on how their body metabolizes and responds to the medication.”

Since starting Ozempic in June 2022, Danielle Griffin has not seen the results her doctor predicted. “She really expected to see a huge difference in my weight, and I just never saw it,” said the 38-year-old from Elida, New Mexico. Griffin weighed about 300 pounds and has lost only about 10 pound in two years. She said her “expectations were pretty much shattered from that.”

Amid insurance battles and shortages, she has also tried Wegovy and Mounjaro, but didn’t see a difference in her weight.

“I don’t feel like there are options, especially for myself, for someone who the medications not working for.”

The prospect of new medications on the horizon excites Griffin. “I would be willing to try it,” she said, adding that “it could be life changing, honestly, and you know that alone gives me something to look forward to.”

More drugs in the pipeline

Eli Lilly, which makes Zepbound and the diabetes version Mounjaro, has two more GLP-1 drugs in development.

On Sunday, Lilly released new data about retatrutide, an injectable drug that combines GLP-1 and glucagon, plus another hormone called GIP. GIP is thought to improve how the body breaks down sugar.

In an earlier trial, retatrutide helped people lose, on average, about 24% of their body weight, the equivalent of about 58 pounds — greater weight loss than any other drug on the market.

New findings showed the weekly medication also significantly reduced blood sugar levels in people with Type 2 diabetes.

On Saturday, there were also new findings on the experimental mazdutide, which Lilly is developing in partnership with the Chinese biotech firm Innovent Biologics. The drug combines GLP-1 and glucagon.

In a phase 3 study of adults in China who were overweight or had obesity, researchers found that after 48 weeks, a 6-milligram dose of the drug led to an average body weight reduction of 14.4%.

The drug also led to a reduction in serum uric acid — a chemical that can build up in the bloodstream, causing health problems, and has been associated with obesity, according to Dr. Linong Ji, director of the Peking University Diabetes Center, who presented the findings.

That was “quite unique and never reported for other GLP-1-based therapies,” he said in an interview.

The drug could be approved in China in 2025, Ji said.

Improving metabolic conditions

An estimated 75% of people with obesity have nonalcoholic fatty liver disease and 34% have MASH, or metabolic dysfunction-associated steatohepatitis, according to researchers with the German drugmaker Boehringer Ingelheim. Fatty liver disease occurs when the body begins to store fat in the liver. It can progress to MASH, when fat buildup causes inflammation and scarring.

In a phase 2 trial of people who were overweight or had obesity, Boehringer Ingelheim’s survodutide, which uses both GLP-1 and glucagon, led to weight loss of 19% at 46 weeks. Another phase 2 study in people with MASH and fibrosis found that 83% of participants also showed improvement in MASH.

Survodutide “has significant potential to make a meaningful difference to people living with cardiovascular, renal and metabolic conditions,” said Dr. Waheed Jamal, Boehringer Ingelheim’s corporate vice president and head of cardiometabolic medicine.

On Friday, the company released two studies on the drug. One, in hamsters, found that weight loss was associated with improvements in insulin and cholesterol. The second, in people with Type 2 diabetes or people with obesity, found the drug helped improve blood sugar levels. 

The company is looking to begin a phase 3 trial.


Source link

Ukrainians in Warsaw jump over a bonfire, float braids to celebrate solstice custom away from home

WARSAW, Poland (AP) — Ukrainians in Warsaw jumped over a bonfire and floated braids to honor the vital powers of water and fire on the Vistula River bank Saturday night, as they celebrated their solstice tradition of Ivan Kupalo Night away from war-torn home. Hundreds joined the event, most of them war refugees.

“We are doing this traditional thing here to keep up our culture which needs all our support now because Russia is trying to kill everything that is Ukrainian,” said Viktoria Pogrebniak, 29, of the Euromaidan-Warszawa social initiative of the Ukrainians that organized the festivities.

“We want the people who have left Ukraine to remember their tradition and to remember that they have a bond with Ukraine,” Pogrebniak told The Associated Press.

Families came with children and dogs for the relaxed event, which also included a small fair with goods and fried sausages to buy. Some people were wearing traditional embroidered shirts and dresses. Women made and wore flower-and-grain ear braids. Proceeds from the event are to help buy drones for the Ukrainian army battling Russia’s invasion.

“People have come and that is really cool that they have not forgotten our traditions and that we are meeting here, even though it’s in Poland and not in Ukraine,” said festively dressed Anastassia Haydamaka, 20, from the western town of Khmelnytskyi.

Rooted in a pagan Slavic tradition of love and fertility, the Kupalo ceremonies mark the advent of summer and are supposed to bring a good harvest and help young girls and boys find good partners in marriage for life. Couples who jump off fire together will live in harmony. Girls float their braids hoping that boys who see them will become their loved husbands.

Linked to water, the tradition was later also associated with St. John the Baptist in Christianity. In Poland, floating off the braids on the year’s shortest night is called St. John’s Night.

Millions of Ukrainian refugees sought safety in Poland after Russia launched a full-scale invasion of their country on Feb.24, 2022. Some have moved on, but nearly 1.5 million are now officially registered for work and social benefits. Some 100,000 Ukrainian children attend schools in Poland, and another 100,000 are in pre-school age here, according to government figures.

.


Source link

Morning exercise may be optimal for improving bone health

A mouse running on a wheel

Morning exercise seemed to improve bone health in mice

Douglas Sacha/GETTY

Morning workouts might make for stronger and longer bones compared with nighttime exercise, according to a study in mice.

Because bone mass starts declining in middle age, it is crucial to keep up with exercise, such as running, jumping and weightlifting, as we age – these movements put force on our bones and keep them strong, similar to how strength training builds muscle.

Lili Chen at the Huazhong University of Science and Technology in China and her colleagues analysed…


Source link

Yankees’ Giancarlo Stanton exits vs. Braves with hamstring tightness


Giancarlo Stanton exited the Yankees’ game against the Braves on Saturday with left hamstring tightness. He will undergo imaging on Sunday, the team announced.

In the fourth inning, Stanton scored from second base on a Gleyber Torres double, which gave the Yankees a 4-1 lead. After rounding third, Stanton appeared to wince on his way to the plate.

Trent Grisham pinch-hit for the designated hitter in the sixth inning. The backup outfielder hit a solo home run later in the game.

Stanton has a long history of lower-body injuries, including a left hamstring strain in April 2023 and a calf strain and Achilles tendonitis in 2022. He hit .202/.286/.442 with 55 home runs, 138 RBI and a league-average 100 OPS+ over those two seasons while playing in 211 games.

In November, Yankees general manager Brian Cashman said that he expected Stanton to get hurt again while discussing Eric Cressey and the team’s 2023 injury woes at the GM Meetings. Those comments didn’t sit well with Stanton and his agent, and Cashman ultimately had to clear the air.

Stanton, meanwhile, revamped his offseason training program. With running now a bigger part of his routine, he came to camp in leaner shape than years past.

The changes have had an impact. Prior to Saturday, Stanton had yet to suffer an injury scare this season. He’s hitting .246 with a .794 OPS, 18 home runs and 45 RBI.


Source link

Weight loss drug Zepbound may help treat sleep apnea, improve blood pressure


A popular obesity drug may help treat a dangerous disorder in which people struggle to breathe while they sleep, a new study finds.

Tirzepatide, the medication in the weight loss drug Zepbound and also the diabetes treatment Mounjaro, appeared to reduce the severity of sleep apnea along with reducing weight and improving blood pressure and other health measures in patients with obesity who took the drug for a year.

Eli Lilly and Co., the drug’s maker who paid for the research, has asked the Food and Drug Administration to expand use of the drug to treat moderate to severe sleep apnea, in which people stop and start breathing during sleep, a spokesperson said Friday. A decision is expected by the end of the year.

But an outside expert cautioned in an editorial that more research will be needed to tell if the drug can be used as “a sole treatment” for obstructive sleep apnea, which occurs when tissue in the throat relaxes and collapses during sleep, fully or partially blocking the airway. It affects an estimated 20 million Americans and can cause short-term issues such as snoring, brain fog and daytime sleepiness but also severe long-term issues such as heart disease, dementia and early death.

The research, published Friday in the New England Journal of Medicine and presented at a medical meeting, included nearly 500 people diagnosed with obesity and sleep apnea. Half of them used what’s typically known as a CPAP machine that feeds oxygen through a mask to keep airways open during sleep. The other group included people for whom a CPAP machine had failed or wasn’t tolerated.

The study found that patients in both groups who got weekly injections of tirzepatide reduced the number of episodes per hour in which their breathing slowed or stopped completely during sleep by about half to nearly 60%, compared to about 10% in people who got a dummy drug

On average, patients who took tirzepatide also lost between 18% and 20% of their body weight and showed improvements in blood pressure and a condition in which blood oxygen drops during sleep. Patients also reported better sleep and fewer sleep disturbances, the study found.

The new research shows that tirzepatide is “a more effective knife in the drawer,” for treating sleep apnea, said lead author Dr. Atul Malhotra, a sleep medicine specialist at the University of California, San Diego.

In an accompanying editorial, Dr. Sanjay Patel, a sleep medicine specialist at the University of Pittsburgh, cautioned that whether tirzepatide can treat sleep apnea in real-world patients “remains unclear” because of the way improvement is measured. He also noted that cost and access remain obstacles to using tirzepatide and that the addition of the drug as a treatment could exacerbate racial and other disparities in addressing sleep apnea.

Dr. Paul Peppard, a sleep medicine researcher at the University of Wisconsin who was not involved in the study, said losing weight has long been recommended as a way to reduce the severity of sleep apnea by expanding lung capacity, reducing fat in the airways and improving oxygen usage. While diet and exercise can spur weight loss and reduce the consequences of the disorder, the ongoing obesity epidemic in the U.S. proves that shedding pounds is difficult for many people, he said. In such cases, medications such as tirzepatide can help.

“I expect that these drugs could be used a a tool to treat many of the established outcomes of obesity,” Peppard said.


Source link

I May Need To Go To The Doctor Because I Physically Can’t Stop Laughing At The 17 Funniest Signs Of The Week

It’s officially summer, and we’re already more than halfway through the year!!! To help cushion the cruel passage of time, please enjoy the funniest signs of the week, courtesy of Twitter and r/funnysigns:

1. “Calm down, Walmart.”

Twitter: @DianaG2772

@DianaG277

2.“Read the sign: this poor cat is starving!”

A cat walks indoors next to a small sign that reads, "feed me you dumb bitch."A cat walks indoors next to a small sign that reads, "feed me you dumb bitch."

3. “Excuse me, I’ll experience what?”

Twitter: @equine__dentist

@equine__dentist

4.“Which one are you?”

Framed illustration showing four ways people squeeze toothpaste tubes, with labels "From Everywhere," "From the Bottom," "From the Top," and "From the Middle."Framed illustration showing four ways people squeeze toothpaste tubes, with labels "From Everywhere," "From the Bottom," "From the Top," and "From the Middle."

5.“But the sign told me too, so it must be OK.”

Wall sign reads, "It's okay to eat a whole pizza by yourself." Below the sign is a table with a small sign holder on itWall sign reads, "It's okay to eat a whole pizza by yourself." Below the sign is a table with a small sign holder on it

6.“They’re up to no good.”

A sign with silhouettes of two geese and the text "DO NOT LET THE GEESE IN THE BUILDING. THEY DO NOT WORK HERE."A sign with silhouettes of two geese and the text "DO NOT LET THE GEESE IN THE BUILDING. THEY DO NOT WORK HERE."

7.“Lemme off, this is my stop.”

Train sign displaying "SLUTSTATION" and "WC" indicating the end of the line and restroom facilitiesTrain sign displaying "SLUTSTATION" and "WC" indicating the end of the line and restroom facilities

8.“Just in case.”

Back of a vehicle with a tightly wrapped object on a luggage rack. A sign reads, "THIS IS NOT AUNT EDNA!"Back of a vehicle with a tightly wrapped object on a luggage rack. A sign reads, "THIS IS NOT AUNT EDNA!"

9.“Do they have one for big ones?”

A daycare named "Little Bitches Day Care" has a sign on a building, with two trash bins placed below itA daycare named "Little Bitches Day Care" has a sign on a building, with two trash bins placed below it

10.“Why though?”

Sign on a fence that reads, "Please Do Not Sit On The Fence," with a roller coaster visible in the backgroundSign on a fence that reads, "Please Do Not Sit On The Fence," with a roller coaster visible in the background

11.“I’ll shut my eyes real tight.”

Sign with text: "THIS IS A PRIVATE SIGN. DO NOT READ."Sign with text: "THIS IS A PRIVATE SIGN. DO NOT READ."

12.“It’s always nice to be offered a choice.”

Laundry care label with humorous instructions: "For Best Results: Machine wash cold. Tumble dry low. Never iron design. For Worst Results: Drag thru puddle behind car. Blow dry on roof rack." 100% polyesterLaundry care label with humorous instructions: "For Best Results: Machine wash cold. Tumble dry low. Never iron design. For Worst Results: Drag thru puddle behind car. Blow dry on roof rack." 100% polyester

13.“But education is for all.”

Sign reads: "Please Do Not Eat in the Library. The ants will get in, learn to read, become too smart. Knowledge is Power. Power Corrupts. Ants will turn evil."Sign reads: "Please Do Not Eat in the Library. The ants will get in, learn to read, become too smart. Knowledge is Power. Power Corrupts. Ants will turn evil."

14.“Funny sign at the fish store.”

Fish in tanks with a sign that reads: "Fish are not dead – just napping."Fish in tanks with a sign that reads: "Fish are not dead – just napping."

15.“Career advice from a sign on a pickup…”

A large sign reads, "My resume is just a list of things I never want to do again." The sign is mounted on a structure near some industrial equipmentA large sign reads, "My resume is just a list of things I never want to do again." The sign is mounted on a structure near some industrial equipment

16.“In case you had doubts…”

A self-checkout machine with multiple signs stating "CARD ONLY!! NO CASH BACK." A shopping area is partially visible in the backgroundA self-checkout machine with multiple signs stating "CARD ONLY!! NO CASH BACK." A shopping area is partially visible in the background

17.“Made me chuckle and think when I saw it.”

Sign with humorous text about theory and practice: "Theory is when you know everything but nothing works. Practice is when everything works but no one knows why. In our lab, theory and practice are combined: Nothing works and no one knows why."Sign with humorous text about theory and practice: "Theory is when you know everything but nothing works. Practice is when everything works but no one knows why. In our lab, theory and practice are combined: Nothing works and no one knows why."

Don’t miss last week’s funniest signs:

18 Signs From The Past Week That Made Me Laugh So Hard, My Face Still Hurts




Source link

Ozempic and Wegovy linked to lower risk of alcoholism

Semaglutide, sold as Ozempic or Wegovy, is given as an injection to treat diabetes or promote weight loss

Marc Bruxelle / Alamy Stock Photo

The weight loss and diabetes drug semaglutide may also help people reduce their alcohol intake.

A study of nearly 700,000 people who were taking the medicine, sold under the brand names Wegovy and Ozempic, adds to a growing body of evidence suggesting the drug may have wider uses in people with a range of addictions.

“This is the strongest evidence yet in humans,”…


Source link